MABQUEST THERAPEUTICS
LIVE

Serial Number

79435367

Owner

MabQuest SA

Attorney

Andrea L. Hintz

Filing Date

Jul 29, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MABQUEST THERAPEUTICS Trademark

Serial Number: 79435367 • Registration: 8258456

MABQUEST THERAPEUTICS is a trademark filed by MabQuest SA on July 29, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

MabQuest SA

Avenue Général-Guisan 62,

Entity Type: 98

Trademark Details

Filing Date

July 29, 2025

Registration Date

May 19, 2026

Published for Opposition

March 31, 2026

Goods & Services

Pharmaceutical products for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; medicinal preparations for disease treatment, namely, for preventing or treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; preparations for medical treatments, in particular preparations based on polypeptides and proteins for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; protein complexes for diagnosing cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; synthetic peptides for pharmaceutical use, namely, for treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; diagnostic agents, preparations and substances for medical purposes; diagnostic substances for medical use; medicinal preparations and substances for preventing and treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; pharmaceutical preparations and substances for preventing and treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; agents and medicines for therapeutic use, namely, for the treatment of cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; cells for medical use; chemical, biochemical and biological preparations being biological, biochemical, and immunological pharmaceutical preparations for medical use

Chemical, biochemical, biological and biotechnological preparations for use in industry and science other than for medical or veterinary use; chemical, biological and biotechnological preparations, in particular polypeptides and proteins for development or manufacture of reagents for use in industry and science; biological preparations, in particular polypeptides or proteins for use in laboratories and for non-medical diagnosis and analysis in industry and science; chemical and biochemical substances being additives for use in the manufacture of pharmaceuticals; chemical and biochemical substances for use in the manufacture of pharmaceuticals for treating cancer, autoimmune diseases, inflammatory disorders, and diseases in the fields of oncology and immunology; stem cells for research purposes; stem cells for scientific use; cultures of microorganisms other than for medical and veterinary use; cell culture media for scientific and research purposes

Analysis and research in laboratories being research laboratory analysis services in the field of chemistry, biochemistry, and molecular biology; scientific research and analysis in the field of chemistry, biochemistry, molecular biology, and immunology; cell culture for scientific research purposes, for others; design and development of medical technologies; research and development in the field of biotechnology; research and development in the field of microorganisms and cells; research and development in the field of diagnostic preparations; pharmaceutical research and development; biochemical research and development; scientific and technological research, particularly in the biochemical, diagnostic or pharmaceutical fields; research and development for the pharmaceutical industry; research and development services in the field of proteins, microorganisms and cells; research and development services in the field of immunology; services of a chemical, biochemical and biological research laboratory; research services, namely, analyses in the field of molecular biology

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 19, 2026 NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 19, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 19, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 31, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 31, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 25, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 10, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 9, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 9, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 9, 2026 TROA
REFUSAL PROCESSED BY IB
Feb 12, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 24, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jan 24, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 15, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 14, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 12, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 27, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 27, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 23, 2025 REPR